Survodutide

Survodutide (research designation BI 456906) is a synthetic dual glucagon (GCG) and GLP-1 receptor agonist developed jointly by Boehringer Ingelheim and Zealand Pharma. Boehringer Ingelheim holds global development and commercialization rights through the licensing agreement with Zealand. The compound is administered as once-weekly subcutaneous injection. It is being developed in parallel programs for obesity (SYNCHRONIZE Phase 3) and MASH (LIVERAGE Phase 3). The compound has received FDA Fast Track designation and China NMPA Breakthrough Therapy designation for the MASH indication.

The molecule is structurally distinct from mazdutide but shares the dual GLP-1/glucagon receptor agonist mechanism. The fatty-acyl modifications enable once-weekly subcutaneous dosing, similar to the engineering used in semaglutide and other modern long-acting peptides. The compound was discovered through Zealand Pharma's peptide drug discovery platform and licensed to Boehringer Ingelheim for clinical development.

The clinical positioning emphasizes two indications:

Obesity (the SYNCHRONIZE program). Targets the same market as mazdutide, semaglutide, tirzepatide, and the broader weight-loss class. Phase 3 SYNCHRONIZE-1 reported 16.6 percent weight loss over 76 weeks, positioning the compound between semaglutide (approximately 15 percent in STEP-1) and tirzepatide (approximately 22 percent in SURMOUNT-1).

MASH and liver fibrosis (the LIVERAGE program). The glucagon receptor component of the dual mechanism drives hepatic lipid oxidation, which is mechanistically relevant for metabolic dysfunction-associated steatohepatitis. The combined effect of GLP-1 (appetite suppression, weight loss) plus glucagon (direct hepatic lipid effects) is particularly well-suited to MASH.

The SYNCHRONIZE Phase 3 Program (Obesity)

The SYNCHRONIZE program is the Phase 3 development for survodutide in obesity.

SYNCHRONIZE-1 (announced April 2026). Phase 3 trial in adults with obesity or overweight. 76 weeks of treatment with survodutide. Mean weight loss was 16.6 percent versus placebo. Maximum weight loss reached 17.8 kg (39.2 lb) from baseline. The trial met both weight-loss primary endpoints and the key secondary endpoint of waist circumference reduction.

Additional SYNCHRONIZE trials. The Phase 3 program includes additional trials (SYNCHRONIZE-2 in patients with type 2 diabetes, additional populations) that are ongoing or planned. The full registrational dataset will support FDA submission in 2026 to 2027.

Comparator positioning. The 16.6 percent SYNCHRONIZE-1 result places survodutide between semaglutide 2.4 mg (approximately 15 percent in STEP-1) and tirzepatide 15 mg (approximately 22 percent in SURMOUNT-1). The drug is competitive with established incretin agents but does not match tirzepatide's efficacy in pure weight-loss terms.

The earlier Phase 2 trial reported up to 19 percent weight loss at higher doses, suggesting the Phase 3 maintenance dose was selected for tolerability rather than maximum effect.

The LIVERAGE Phase 3 Program (MASH)

The LIVERAGE program is the Phase 3 development for survodutide in metabolic dysfunction-associated steatohepatitis.

Indication scope. Adults with non-cirrhotic MASH and moderate or advanced fibrosis (stages F2 or F3). This patient population is the primary target for MASH-directed therapies.

Regulatory recognition. Survodutide has received FDA Fast Track designation for MASH and China NMPA Breakthrough Therapy designation. These regulatory recognitions reflect the unmet medical need in MASH and the mechanistic relevance of the dual GLP-1/glucagon approach.

Phase 2 LIVERAGE data. The Phase 2 trial in MASH reported substantial reductions in liver fat content, improvements in liver enzyme levels, and metabolic improvements alongside weight loss. The Phase 3 LIVERAGE trials are extending these findings to longer follow-up and harder MASH endpoints (NASH resolution, fibrosis reduction).

The MASH treatment environment. Resmetirom (Rezdiffra) received FDA accelerated approval in March 2024 as the first MASH-specific drug. Survodutide would be the first dual incretin/glucagon approach to MASH. The two mechanisms are mechanistically complementary and may eventually be used in combination.

Survodutide activates both glucagon and GLP-1 receptors with the same combinatorial logic as mazdutide.

GLP-1 receptor activation. Standard incretin effects: appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion, reduced glucagon release in pancreatic alpha cells.

Glucagon receptor activation. Increases energy expenditure and hepatic lipid oxidation. The hepatic effects are particularly relevant for MASH where liver fat accumulation is the central pathology. Glucagon receptor activation drives lipolysis and beta-oxidation in liver tissue, directly reducing hepatic triglyceride content.

Combined effects on body composition. The dual mechanism produces weight loss alongside improvements in waist circumference (a cardiometabolic risk indicator), improved liver fat content, and metabolic improvements that extend beyond weight loss alone.

The MASH mechanism. MASH is characterized by liver fat accumulation, inflammation, and fibrosis. GLP-1 agonists alone produce some MASH improvement through weight loss. Glucagon receptor activation adds direct hepatic effects that may improve MASH independently of weight loss. The combination is mechanistically more relevant to MASH than pure GLP-1 agonism.

The pharmacokinetic profile supports once-weekly subcutaneous administration. The compound's structural modifications protect against rapid peptidase degradation similar to other long-acting peptide engineering.

Regulatory status

United States. Phase 3 SYNCHRONIZE and LIVERAGE programs ongoing. FDA Fast Track designation for MASH. NDA submission anticipated 2026 to 2027 following completion of Phase 3 programs. No FDA approval as of May 2026.

China. China NMPA Breakthrough Therapy designation for MASH. Phase 3 development in parallel with US development.

EU. EMA submission anticipated to follow FDA submission. Standard pattern for new obesity and MASH drugs.

Boehringer Ingelheim holds global development and commercialization rights. Zealand Pharma receives milestone payments and royalties under the licensing agreement.

WADA status. Survodutide is not currently named on the WADA Prohibited List as a specific substance. It would fall under section S4 (Hormone and Metabolic Modulators) by analogy with other GLP-1 agonists.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The SYNCHRONIZE-1 and earlier Phase 2 safety data have been broadly consistent with the GLP-1 class profile.

Gastrointestinal effects dominate. Nausea, diarrhea, vomiting, and constipation are most common during dose escalation.

Mild heart rate increase consistent with GLP-1 class effects.

Injection-site reactions common but mild.

Glucagon-related considerations. The glucagon receptor activation has theoretical implications for glucose regulation (the normal physiology of glucagon increases blood glucose), but the combined GLP-1/glucagon balance in the compound preserves glucose control. No clinical hyperglycemia signal has emerged in trials.

MASH-specific safety. In the MASH patient population, the compound's tolerability profile has been described as consistent with the broader incretin class. The Phase 3 LIVERAGE program will provide additional safety data in the MASH population specifically.

The dual mechanism has not produced unexpected adverse effects beyond the expected GLP-1 and glucagon receptor pharmacology.

The dual GLP-1/glucagon agonist class now has two competitive entries plus the triple agonist retatrutide.

Survodutide vs Mazdutide. Both are dual GLP-1/glucagon agonists. Mazdutide received the first regulatory approval (China NMPA, June 2025). Survodutide has more advanced Western development and broader indication coverage (MASH in addition to obesity). The two are direct competitors in the same mechanism class. Different commercial sponsors (Boehringer/Zealand vs Innovent/Lilly).

Survodutide vs Semaglutide. Semaglutide is GLP-1 only. Survodutide adds glucagon receptor activation. The glucagon component drives additional hepatic effects relevant to MASH. Survodutide produces approximately 16.6 percent weight loss versus 15 percent for semaglutide 2.4 mg, similar pure weight-loss efficacy with potentially better liver effects.

Survodutide vs Tirzepatide. Tirzepatide is GLP-1/GIP. Survodutide is GLP-1/GCG. Different second receptors produce different metabolic profiles. Tirzepatide has higher pure weight-loss efficacy (approximately 22 percent vs 16.6 percent). Survodutide may have better hepatic effects through glucagon activation.

Survodutide vs Retatrutide. Retatrutide combines GLP-1/GIP/GCG (triple agonist). It is the next layer of mechanism expansion. Retatrutide produces approximately 28.7 percent weight loss in TRIUMPH-4. The triple agonist is anticipated to outperform dual agonists on pure weight loss but the relative performance on hepatic and other organ-specific effects is still being established.

For MASH specifically, survodutide's combination of regulatory designations (FDA Fast Track + China Breakthrough) and mechanistic relevance positions it as the leading dual-agonist candidate. The MASH indication may differentiate survodutide from mazdutide, which has focused primarily on obesity and diabetes.